Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H18N4O4 |
Molecular Weight | 270.285 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC=C(N1CC(O)CN2CCOCC2)[N+]([O-])=O
InChI
InChIKey=GAZGHCHCYRSPIV-UHFFFAOYSA-N
InChI=1S/C11H18N4O4/c1-9-12-6-11(15(17)18)14(9)8-10(16)7-13-2-4-19-5-3-13/h6,10,16H,2-5,7-8H2,1H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22184458Curator's Comment: description was created based on several sources, including: DOI: 10.5897/AJPP12.1353 | https://www.ncbi.nlm.nih.gov/pubmed/25070100 | https://newdrugapprovals.org/2015/08/11/morinidazole/ | https://www.ncbi.nlm.nih.gov/pubmed/24858695
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22184458
Curator's Comment: description was created based on several sources, including: DOI: 10.5897/AJPP12.1353 | https://www.ncbi.nlm.nih.gov/pubmed/25070100 | https://newdrugapprovals.org/2015/08/11/morinidazole/ | https://www.ncbi.nlm.nih.gov/pubmed/24858695
Morinidazole is a novel third generation 5-nitroimidazole-class antimicrobial agent indicated for the treatment of anaerobic bacterial infections including appendicitis and pelvic inflammatory disease. Morinidazole is administered as a racemate. Morinidazole was approved by China Food and Drug Administration (CFDA) on February, 2014. The bactericidal activity of morinidazole, depends on the formation of a redox intermediate metabolite in the bacterium that causes DNA strand breakage, inhibits repair, and, ultimately leads to cell death. The main adverse effects (all are mild) relate to the drug are dizziness, drowsiness and nausea. Recent in vitro assays have demonstrated that higher antiparasitic potency is observed in S- morinidazole than in R-morinidazole.
Originator
Sources: https://www.pharmacodia.com/yaodu/html/v1/chemicals/c5d736809766d46260d816d8dbc9eb44.html
Curator's Comment: https://newdrugapprovals.org/2015/08/11/morinidazole/
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1743319 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25070100 |
|||
Target ID: GO:0036473 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22184458 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | 迈灵达® (Mindlinga®) Approved UseMorinidazole is a nitroimidazoles antibiotic indicated for the treatment of bacterial infections including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria. Launch Date2014 |
|||
Curative | 迈灵达® (Mindlinga®) Approved UseMorinidazole is a nitroimidazoles antibiotic indicated for the treatment of bacterial infections including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria. Launch Date2014 |
|||
Sources: DOI: 10.5897/AJPP12.1353 |
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Metabolism and pharmacokinetics of morinidazole in humans: identification of diastereoisomeric morpholine N+-glucuronides catalyzed by UDP glucuronosyltransferase 1A9. | 2012 Mar |
|
Pharmacokinetics of single-dose morinidazole in patients with severe renal impairment. | 2014 Feb |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.pharmacodia.com/web/drug/1_477.html
500 mg (100 mL injection) twice daily every 6-8 hours continuously for 5-7 days
Route of Administration:
Intravenous
Minimum inhibitory concentration (MIC) of Morinidazole to several anaerobic bacteria: Peptostreptococcus anaerobius (0.25 mg/l); Veillonella parvula (0.31 mg/l); Actinomyces dentocariosus (0.25 mg/l); Porphyromonas gingivalis (2.0 mg/l); Bacteroides thetaiotaomicron (4.0); Prevotella melaninogenica (0.5 mg/l).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TUPWG40JAL
Created by
admin on Sat Dec 16 13:30:57 GMT 2023 , Edited by admin on Sat Dec 16 13:30:57 GMT 2023
|
PRIMARY | |||
|
C184884
Created by
admin on Sat Dec 16 13:30:57 GMT 2023 , Edited by admin on Sat Dec 16 13:30:57 GMT 2023
|
PRIMARY | |||
|
5255
Created by
admin on Sat Dec 16 13:30:57 GMT 2023 , Edited by admin on Sat Dec 16 13:30:57 GMT 2023
|
PRIMARY | |||
|
DTXSID201031280
Created by
admin on Sat Dec 16 13:30:57 GMT 2023 , Edited by admin on Sat Dec 16 13:30:57 GMT 2023
|
PRIMARY | |||
|
DB15098
Created by
admin on Sat Dec 16 13:30:57 GMT 2023 , Edited by admin on Sat Dec 16 13:30:57 GMT 2023
|
PRIMARY | |||
|
100000182561
Created by
admin on Sat Dec 16 13:30:57 GMT 2023 , Edited by admin on Sat Dec 16 13:30:57 GMT 2023
|
PRIMARY | |||
|
11830
Created by
admin on Sat Dec 16 13:30:57 GMT 2023 , Edited by admin on Sat Dec 16 13:30:57 GMT 2023
|
PRIMARY | |||
|
92478-27-8
Created by
admin on Sat Dec 16 13:30:57 GMT 2023 , Edited by admin on Sat Dec 16 13:30:57 GMT 2023
|
PRIMARY | |||
|
11644726
Created by
admin on Sat Dec 16 13:30:57 GMT 2023 , Edited by admin on Sat Dec 16 13:30:57 GMT 2023
|
PRIMARY | |||
|
SUB196717
Created by
admin on Sat Dec 16 13:30:57 GMT 2023 , Edited by admin on Sat Dec 16 13:30:57 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)